FDAnews
www.fdanews.com/articles/72585-guilford-reports-promising-results-in-study-of-gliadel

Guilford Reports Promising Results in Study of Gliadel

May 23, 2005

Guilford Pharmaceuticals has announced findings from a study of Gliadel Wafer (polifeprosan 20 with carmustine) and temozolomide used in combination to treat adult patients with newly diagnosed, high-grade malignant glioma.

Results of the ongoing, Phase II, multicenter, single-arm trial show acceptable toxicities when combining the two chemotherapeutic agents, and suggest that the combination may be given safely to patients with initial high grade malignant glioma.

During the trial, patients underwent surgical resection followed by implantation of Gliadel, a localized chemotherapy inserted directly into the resection cavity. Patients were then treated with oral daily temozolomide and standard radiotherapy, followed by up to 18 cycles of oral monthly temozolomide.